PD-1话题

重磅汇总:近2月内发布的PD1抗癌数据

LensNews

 

直奔主题,汇总2017年6月1日以来的5项PD1抑制剂重磅数据。

 

权威发布:PD-1“联合”放疗,生存期翻倍!

 

参考文献:
[1]Parakh S, Park JJ, Mendis S, et al. Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases. Br J Cancer. 2017 Jun 6;116(12):1558-1563
[2]Apolo AB, Infante JR, Balmanoukian A, et al. Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study. J Clin Oncol. 2017 Jul 1;35(19):2117-2124.
[3]Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma. Blood. 2017 Jul 20;130(3):267-270
[4]Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. J Clin Oncol. 2017 Aug 1;35(22):2535-2541.

添加咚咚客服助手小橙(微信号:dongdongkfxc,注明咚咚官网会员),获取更多PD-1资料、临床信息、药物渠道、线下活动及抗癌最新资讯 。下载咚咚肿瘤科app,还可与全国十强肿瘤医院医生实时交流咨询。

(0)
Loading收藏(0)

本文由 咚咚肿瘤科 作者:小D 发表,转载请注明来源!

LensNews